Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 70

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 5
Chunk 70
---
 initial activities for use of avenanthramides in nutraceuticals were focused on assessing the bio-availability and bio-efficacy
of the compound under the leadership of Dr. Li Li Ji at the University of Minnesota. Following the completion of the bio-availablity
study in 2018, the Company successfully completed two bio-efficacy studies in 2019 using low and high doses of avenanthramides with young
men and women demonstrating in a statistically significant manner the efficacy of avenanthramides in alleviating exercise-induced inflammation
as evidenced by a significant decrease of inflammation biomarkers in the blood. These studies paved the way for the development of products
like superfine oat flour enriched with Avenanthramides used for the production of chewable oat bar as a nutraceutical as well as for
the development of a pharmaceutical grade tablet for clinical trials. The Company is initiating the production of enriched oat flour
at small commercial scale at the Edmonton facility.

Beta
glucan from yeast (YBG)- nutraceutical-capsule as an immune booster

While
yeast beta glucan is a commercial product with well-known immune properties, the obtention of a consistently high-purity product represents
a major challenge for suppliers. Using the PGX technology, the Company has successfully processed several formulations of yeast beta
glucan and is now in a position to offer a very high purity YBG product with very well-defined specifications. The Company further demonstrated
the mechanism of action following in vitro in vivo

This
product has been used for the completion of the 50-liter PGX technology vessel at the Edmonton facility and will also be used for the
100-liter PGX technology vessel work being conducted in Austria. Powder formulation produced in Edmonton will be offered in capsules
as an immune booster product.

Pharmaceutical

The
Company is also dedicated to the development of its pharmaceutical therapeutic assets and has established a clinical and pre-clinical
development pipeline to potentially address unmet medical needs across a number of indications, including diagnostic tests for growth
hormone deficiency and potential treatment of inflammation based diseases.

During
the third quarter of 2024, the Company made a strategic decision to discontinue its AIM Biological, Amyotrophic Lateral Sclerosis (ALS),
and Delayed Clearance Parathyroid Hormone programs. This decision was influenced by several factors, including increasingly challenging
timelines and costs associated with reaching the next value inflection point in pre-clinical development